Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.

French JD, Johnatty SE, Lu Y, Beesley J, Gao B, Kalimutho M, Henderson MJ, Russell AJ, Kar S, Chen X, Hillman KM, Kaufmann S, Sivakumaran H, O'Reilly M, Wang C, Korbie DJ; Australian Ovarian Cancer Study Group; Australian Ovarian Cancer Study, Lambrechts D, Despierre E, Van Nieuwenhuysen E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching PA, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Pisterer J, Hillemanns P, Nakanishi T, Yatabe Y, Goodman MT, Lurie G, Matsuno RK, Thompson PJ, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan JM, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut JM, Iversen E, Weber RP, Brennan D, Berchuck A, Pharoah P, Harnett P, Norris MD, Haber M, Goode EL, Lee JS, Khanna KK, Meyer KB, Chenevix-Trench G, deFazio A, Edwards SL, MacGregor S; Ovarian Cancer Association Consortium.

Oncotarget. 2016 Feb 9;7(6):6353-68. doi: 10.18632/oncotarget.7047.

2.

ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.

Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J; Australian Ovarian Cancer Study Group, Williams RT, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan J, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber RP, Berchuck A, Goode E, Bowtell DD, Chenevix-Trench G, deFazio A, Norris MD, MacGregor S, Haber M, Henderson MJ.

J Natl Cancer Inst. 2014 Jun 23;106(7). pii: dju149. doi: 10.1093/jnci/dju149. Print 2014 Jul.

3.

Opioids and efflux transporters. Part 4: influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues.

Metcalf MD, Rosicky AD, Hassan HE, Eddington ND, Coop A, Cunningham CW, Mercer SL.

Bioorg Med Chem Lett. 2014 Aug 1;24(15):3592-5. doi: 10.1016/j.bmcl.2014.05.033. Epub 2014 May 22.

4.

Ligand requirements for involvement of PKCε in synergistic analgesic interactions between spinal μ and δ opioid receptors.

Schuster DJ, Metcalf MD, Kitto KF, Messing RO, Fairbanks CA, Wilcox GL.

Br J Pharmacol. 2015 Jan;172(2):642-53. doi: 10.1111/bph.12774. Epub 2014 Nov 24.

5.

The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptors.

Metcalf MD, Yekkirala AS, Powers MD, Kitto KF, Fairbanks CA, Wilcox GL, Portoghese PS.

ACS Chem Neurosci. 2012 Jul 18;3(7):505-9. doi: 10.1021/cn3000394. Epub 2012 May 22.

6.

Systemic inflammation and insulin sensitivity in obese IFN-γ knockout mice.

O'Rourke RW, White AE, Metcalf MD, Winters BR, Diggs BS, Zhu X, Marks DL.

Metabolism. 2012 Aug;61(8):1152-61. doi: 10.1016/j.metabol.2012.01.018. Epub 2012 Mar 3.

7.

Hypoxia-induced inflammatory cytokine secretion in human adipose tissue stromovascular cells.

O'Rourke RW, White AE, Metcalf MD, Olivas AS, Mitra P, Larison WG, Cheang EC, Varlamov O, Corless CL, Roberts CT Jr, Marks DL.

Diabetologia. 2011 Jun;54(6):1480-90. doi: 10.1007/s00125-011-2103-y. Epub 2011 Mar 13.

8.

Depot-specific differences in inflammatory mediators and a role for NK cells and IFN-gamma in inflammation in human adipose tissue.

O'Rourke RW, Metcalf MD, White AE, Madala A, Winters BR, Maizlin II, Jobe BA, Roberts CT Jr, Slifka MK, Marks DL.

Int J Obes (Lond). 2009 Sep;33(9):978-90. doi: 10.1038/ijo.2009.133. Epub 2009 Jun 30.

9.

The influence of esters and carboxylic acids as the N-substituent of opioids. Part 1: Benzomorphans.

Metcalf MD, Aceto MD, Harris LS, Woods JH, Traynor JR, Coop A, May EL.

Bioorg Med Chem. 2008 Jan 15;16(2):869-73. Epub 2007 Oct 13.

10.

5'-halogenated analogs of oxymorphindole.

Metcalf MD, Coop A.

Bioorg Med Chem Lett. 2007 Nov 1;17(21):5916-7. Epub 2007 Aug 23.

11.

Kappa opioid antagonists: past successes and future prospects.

Metcalf MD, Coop A.

AAPS J. 2005 Oct 27;7(3):E704-22. Review.

12.

Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases).

Storek J, Zhao Z, Lin E, Berger T, McSweeney PA, Nash RA, Akatsuka Y, Metcalf MD, Lu H, Kalina T, Reindl M, Storb R, Hansen JA, Sullivan KM, Kraft GH, Furst DE, Maloney DG.

Clin Immunol. 2004 Dec;113(3):285-98.

13.

Rearrangement of 5-trimethylsilylthebaine on treatment with L-selectride: an efficient synthesis of (+)-bractazonine.

Chen W, Wu H, Bernard D, Metcalf MD, Deschamps JR, Flippen-Anderson JL, MacKerell AD Jr, Coop A.

J Org Chem. 2003 Mar 7;68(5):1929-32.

PMID:
12608812
14.

The acute hemodynamic effects of right ventricular septal pacing in patients with congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

Gold MR, Shorofsky SR, Metcalf MD, Feliciano Z, Fisher ML, Gottlieb SS.

Am J Cardiol. 1997 Mar 1;79(5):679-81.

PMID:
9068534

Supplemental Content

Loading ...
Support Center